SEARCH

SEARCH BY CITATION

References

  • 1
    Hansen A-BE, Gerstoft J, Kronborg G, Larsen CS, Pedersen C, Pedersen G, Obel N. Incidence of low high-energy fractures in persons with without HIV infection: a Danish population-based cohort study. AIDS 26(3):28593.
  • 2
    Dolan SE, Kanter JR, Grinspoon S. Longitudinal analysis of bone density in human immunodeficiency virus-infected women. J Clin Endocrinol Metab. 2012; 2006; 91(8):293845.
  • 3
    Yin MT, McMahon DJ, Ferris DC, Zhang CA, Shu A, Staron R, Colon I, Laurence J, Dobkin JF, Hammer SM, Shane E. Low bone mass and high bone turnover in postmenopausal human immunodeficiency virus-infected women. J Clin Endocrinol Metab. 2010; 95(2):6209.
  • 4
    Arnsten JH, Freeman R, Howard AA, Floris-Moore M, Lo Y, Klein RS. Decreased bone mineral density increased fracture risk in aging men with or at risk for HIV infection. AIDS. 2007; 21(5):61723.
  • 5
    Sims NA, Gooi JH. Bone remodeling: multiple cellular interactions required for coupling of bone formation and resorption. Semin Cell Dev Biol. 2008; 19(5):44451.
  • 6
    Ding C, Parameswaran V, Udayan R, Burgess J, Jones G. Circulating levels of inflammatory markers predict change in bone mineral density and resorption in older adults: a longitudinal study. J Clin Endocrinol Metab. 2008; 93(5):19528.
  • 7
    Aukrust P, Haug CJ, Ueland T, Lien E, Muller F, Espevik T, Bollerslev J, Froland SS. Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone-remodeling process during highly active antiretroviral therapy. J Clin Endocrinol Metab. 1999; 84(1):14550.
  • 8
    Hernandez Quero J, Ortego N, Centeno M, Munoz-Torres M, Martinez Perez MA, Higuera Torres-Puchol JM. Alterations in bone turnover in HIV-positive patients. Infection. 1993; 21(4):2202.
  • 9
    Serrano S, Marinoso ML, Soriano JC, Rubies-Prat J, Aubia J, Coll J, Bosch J, Del Rio L, Vila J, Goday A, Nacher M. Bone remodelling in human immunodeficiency virus-1-infected patients. A histomorphometric study. Bone. 1995; 16(2):18591.
  • 10
    Yin MT, Shane E. Low bone-mineral density in patients with HIV: pathogenesis and clinical significance. Curr Opin Endocrinol Diabetes. 2006; 13(6):497502.
  • 11
    Stellbrink H-J, Orkin C, Arribas JR, Compston J, Gerstoft J, Van Wijngaerden E, Lazzarin A, Rizzardini G, Sprenger HG, Lambert J, Sture G, Leather D, Hughes S, Zucchi P, Pearce H, Group AS. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis. 2010; 51(8):96372.
  • 12
    van Vonderen MG, Mallon P, Murray B, Doran P, Agtmael MV, Danner S, Lips P, Reiss P, Group FMS. Changes in bone biomarkers in ARV-naïve HIV+ men randomized to NVP/LPV/r or AZT/3TC/LPV/r help explain limited loss of bone mineral density over the first 12 months after ART initiation. 18th Conference on Retroviruses and Opportunistic Infections (CROI); February 27–March 2. 2011; Boston, MA.
  • 13
    The SMART Study Group. CD4+ guided antiretroviral treatment interruption: primary results of the SMART study. N Engl J Med. 2006; 355:228396.
  • 14
    Grund B, Peng G, Gibert C, Hoy J, Isaksson R, Shlay J, Martinez E, Reiss P, Visnegarwala F, Carr A, Sub ISBC. Continuous antiretroviral therapy decreases bone mineral density. AIDS. 2009; 23(12):151929.
  • 15
    Martinez E, Visnegarwala F, Grund B, Thomas A, Gibert C, Shlay J, Drummond F, Pearce D, Edwards S, Reiss P, El-Sadr W, Carr A, Grp ISS. The effects of intermittent, CD4-guided antiretroviral therapy on body composition metabolic parameters. AIDS. 2010; 24(3):35363.
  • 16
    Grund B, Sabin C. Analysis of biomarker data: logs odds ratios receiver operating characteristic curves. Curr Opin HIV AIDS. 2010; 5(6):4739.
  • 17
    Harrell FE. Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis. New York: Springer; 2001.
  • 18
    Team RDC. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. 2012.
  • 19
    Jabbar S, Drury J, Fordham JN, Datta HK, Francis RM, Tuck SP. Osteoprotegerin, RANKL and bone turnover in postmenopausal osteoporosis. J Clin Pathol. 2011; 64(4):3547.
  • 20
    Brown TT, Ross AC, Storer N, Labbato D, McComsey GA. Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens. Antiviral Ther. 2011; 16(7):106372.
  • 21
    Abitbol V, Roux C, Chaussade S, Guillemant S, Kolta S, Dougados M, Couturier D, Amor B. Metabolic bone assessment in patients with inflammatory bowel disease. Gastroenterology. 1995; 108(2):41722.
  • 22
    Schett G, David JP. The multiple faces of autoimmune-mediated bone loss. Nat Rev Endocrinol. 2010; 6(12):698706.
  • 23
    Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogoch ER, Van G, Nguyen LT, Ohashi PS, Lacey DL, Fish E, Boyle WJ, Penninger JM. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature. 1999; 402(6759):3049.
  • 24
    Clowes JA, Riggs BL, Khosla S. The role of the immune system in the pathophysiology of osteoporosis. Immunol Rev. 2005; 208:20727.
  • 25
    Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997; 89(2):30919.
  • 26
    Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998; 93(2):16576.
  • 27
    Ofotokun I, Weitzmann N, Vunnava A, Sheth A, Villinger F, Zhou J. HAART-induced immune reconstitution: a driving force behind bone resorption in HIV/AIDS. 18th Conference on Retroviruses and Opportunistic Infections (CROI); February 27–March 2. 2011; Boston, MA.
  • 28
    Ofotokun I, McIntosh E, Weitzmann MN. HIV: inflammation and bone. Curr HIV/AIDS Rep. 2012; 9(1):1625.